Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $994646.0.

  • BioNexus Gene Lab's Cash from Investing Activities rose 58958.75% to $994646.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 19636.85%. This contributed to the annual value of $418202.0 for FY2024, which is 12330.85% up from last year.
  • Latest data reveals that BioNexus Gene Lab reported Cash from Investing Activities of $994646.0 as of Q3 2025, which was up 58958.75% from -$28532.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Cash from Investing Activities' 5-year high stood at $994646.0 during Q3 2025, with a 5-year trough of -$1.4 million in Q4 2023.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$49903.0 (2022), whereas its average is -$71926.5.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 275629.72% in 2023, then surged by 217030.74% in 2024.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Cash from Investing Activities stood at -$76289.0 in 2021, then skyrocketed by 34.59% to -$49903.0 in 2022, then crashed by 2756.3% to -$1.4 million in 2023, then surged by 138.9% to $554402.0 in 2024, then skyrocketed by 79.41% to $994646.0 in 2025.
  • Its Cash from Investing Activities was $994646.0 in Q3 2025, compared to -$28532.0 in Q2 2025 and -$15646.0 in Q1 2025.